Your browser doesn't support javascript.
loading
Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
Shaib, Walid L; Manali, Rupji; Liu, Yuan; El-Rayes, Bassel; Loehrer, Patrick; O'Neil, Bert; Cohen, Steven; Khair, Tina; Robin, Erwin; Huyck, Timothy; Bekaii-Saab, Tanios.
Afiliação
  • Shaib WL; Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: wshaib@emory.edu.
  • Manali R; Department of Biostatistics, Emory University, Atlanta, GA, USA.
  • Liu Y; Department of Biostatistics, Emory University, Atlanta, GA, USA.
  • El-Rayes B; Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Loehrer P; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.
  • O'Neil B; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN, USA.
  • Cohen S; Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA.
  • Khair T; Gettysburg Cancer Center, Pennsylvania Cancer Specialists, PA, USA.
  • Robin E; NorthShore University Health System-Metro Chicago, Evanston, IL, USA.
  • Huyck T; Nebraska Cancer Specialists, Omaha, NE, USA.
  • Bekaii-Saab T; Mayo Clinic, Scottsdale, AZ, USA.
Eur J Cancer ; 189: 112847, 2023 08.
Article em En | MEDLINE | ID: mdl-37268519
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article